Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.56 |
| ▸ | GLP1R | P43220 | 9/20 | 0.55 |
| ▸ | SCTR | P47872 | 1/20 | 0.55 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.55 |
| ▸ | APLNR | P35414 | 1/20 | 0.55 |
| ▸ | GCGR | P47871 | 1/20 | 0.52 |
| ▸ | GIPR | P48546 | 1/20 | 0.52 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | CALCR | P30988 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567761 | 0.91 | GLP1R (0.60) | TFPIGLP1RSCTRIL23RGCGR | |
| SCHEMBL30567777 | 0.91 | PTH1R (0.61) | GLP1RPTH1RCALCR | |
| SCHEMBL30432835 | 0.91 | IL23R (0.57) | GLP1RSCTRIL23RGCGRGIPR | |
| SCHEMBL31182575 | 0.90 | TFPI (0.63) | TFPIGLP1RSCTRGCGRGIPR | |
| SCHEMBL30436184 | 0.89 | GLP1R (0.62) | TFPIGLP1RSCTRIL23RPTH1R | |
| SCHEMBL30567726 | 0.89 | GLP1R (0.58) | GLP1RSCTRPTH1RCALCR | |
| SCHEMBL31307236 | 0.89 | TFPI (0.57) | TFPIGLP1RSCTRGCGRGIPR | |
| SCHEMBL30262193 | 0.89 | PTH1R (0.64) | GLP1RAPLNRPTH1RCALCR | |
| SCHEMBL30432505 | 0.88 | GLP1R (0.66) | GLP1RSCTRPTH1RCALCR | |
| SCHEMBL30432625 | 0.87 | PTH1R (0.59) | GLP1RSCTRAPLNRPTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277841-A2 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-22 | — | — | US | disclosed |
| US-20240024473-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2024-01-25 | — | — | US | disclosed |
| CN-116601290-A | Human chimeric antigen receptor neutrophils, compositions, kits and methods of use | 普渡研究基金会 | 2023-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277841-A2 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PBK, KIT, MYD88 | TFPI 1593/4885GLP1R 2288/4885SCTR 228/4885 |
| US-20240024473-A1 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | PBK, KIT, MYD88 | TFPI 1593/4885GLP1R 2288/4885SCTR 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.